View and download slide summaries of the latest original articles focusing on therapies in immune-mediated inflammatory diseases including rheumatology, dermatology, and gastroenterology. All materials produced by the team are subsequently reviewed and approved by individual Steering Committee members.
BioDrugs. 2025 Mar;39(2):297-306 doi: 10.1007/s40259-025-00705-5
IL23is are associated with a lower risk of PsA incidence compared to IL17is in PsO patients, particularly in specific age, sex, and ethnic groups according to the latest real-world research from Yu S, et al.
Clin Exp Dermatol. 2025 Apr 24;50(5):952-959 doi: 10.1093/ced/llae530. PMID: 39657275.
Real-world effectiveness and safety data suggest that deucravacitinib is a valuable long-term treatment option for PsO.
Lancet Rheumatol. 2025;7:e274–89 doi: 10.1016/S2665-9913(24)00340-0
Nagy et al. propose a unifying and holistic framework for understanding and addressing the concept of difficult-to-treat (D2T) disease across rheumatology, integrating cross-disciplinary evidence and recommending its incorporation into future disease management strategies. The D2T state requires a comprehensive, holistic, multidisciplinary approach that considers the specific characteristics of each disease and the personalised needs of the patient.
RMD Open. 2025;11:e005033. doi: 10.1136/rmdopen-2024-005033.
Mariette et al. investigated the long-term safety of filgotinib with regard to MACE, VTE and malignancy across RA and UC clinical trial populations. Rates of these events remained low overall, with some increases observed in patients aged 65 years and older.
Drug Safety. 2025. Epub ahead of print. doi: 10.1007/s40264-025-01535-
Di Napoli et al. conducted a global pharmacovigilance analysis comparing MACE between JAKis and anti-TNFα therapies in patients with RA. JAKis were more frequently associated with reported MACE, particularly stroke, and had a shorter median time to onset than
anti-TNFα therapy.
Clin. Ther. 2025;47:293–297 doi: 10.1016/j.clinthera.2025.01.005
Zhao et al. found that among patients with PsA or axSpA, JAKi were not associated with increased risk of CVD or common cancers compared to TNFi or IL-17i.
Arthritis Rheumatol. 2025;77:253–262 doi: 10.1002/art.43014.
Eberhard et al. investigated the effectiveness of JAKi versus bDMARDs on pain reduction in RA patients, using Swedish national register data. JAKi treatment resulted in a significantly greater reduction in pain at three months compared with TNFis, with a higher proportion achieving low pain at 12 months, particularly in those previously treated with multiple bDMARDs.
